BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38138255)

  • 1. CD8-Lymphocytic Phenotype Significance in Primary Multiple and Familial Melanoma with Various CDKN2A Mutational Status.
    Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Bălțătescu GI; Orășanu CI; Boşoteanu M
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138255
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunophenotypic p14 and p16 correlations with CDKN2A mutations in primary multiple and familial melanoma: An observational study.
    Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Orășanu CI; Boşoteanu M
    Medicine (Baltimore); 2023 Dec; 102(51):e36756. PubMed ID: 38134090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
    Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
    Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
    Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
    Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Confocal Morphologic Classification and Clinical Phenotypes of Multiple Primary and Familial Melanomas.
    Grazziotin TC; Alarcon I; Bonamigo RR; Carrera C; Potrony M; Aguilera P; Puig-Butillé JA; Brito J; Badenas C; Alós L; Malvehy J; Puig S
    JAMA Dermatol; 2016 Oct; 152(10):1099-1105. PubMed ID: 27579522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic Differences in Tumor-Infiltrating Lymphocytes and Neovascularization Between Primary Cutaneous Melanoma With and Without Metastasis: An Immunohistochemical Study of 80 Cases.
    Salgüero I; Roustán G; Requena L; Suárez D; García-Fresnadillo D; Redondo JI; Nájera L
    Am J Dermatopathol; 2021 Nov; 43(11):811-818. PubMed ID: 33534211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.
    Fujii H; Arakawa A; Utsumi D; Sumiyoshi S; Yamamoto Y; Kitoh A; Ono M; Matsumura Y; Kato M; Konishi K; Shiga T; Sano S; Sakaguchi S; Miyagawa-Hayashino A; Takahashi K; Uezato H; Miyachi Y; Tanioka M
    Int J Cancer; 2014 May; 134(10):2393-402. PubMed ID: 24243586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
    Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
    Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.
    Taylor NJ; Handorf EA; Mitra N; Avril MF; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
    J Invest Dermatol; 2016 May; 136(5):1066-1069. PubMed ID: 26827760
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
    Krishna Y; McCarthy C; Kalirai H; Coupland SE
    Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
    Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
    J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of tumor infiltrating lymphocytes in sinonasal mucosal melanoma and prognosis for patients.
    Yin G; Guo W; Liu H; Huang Z; Chen X
    Curr Probl Cancer; 2022 Aug; 46(4):100878. PubMed ID: 35752137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma.
    Berg P; Wennberg AM; Tuominen R; Sander B; Rozell BL; Platz A; Hansson J
    Melanoma Res; 2004 Aug; 14(4):251-5. PubMed ID: 15305154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas.
    Škuciová V; Drahošová S; Výbohová D; Cígerová V; Adamkov M
    Pathol Res Pract; 2020 Sep; 216(9):153071. PubMed ID: 32825944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.